CHAPEL HILL, N.C.--(BUSINESS WIRE)--G1 Therapeutics, Inc. today announced that the company has partnered with Hatteras Venture Partners (HVP) to advance their drug discovery pipeline. G1 is progressing several novel pre- clinical small molecule inhibitors forward to provide protection of bone marrow and other organs against radiologic and chemotherapeutic insults. G1 Therapeutics was founded by Dr. Norman Sharpless, Associate Director for Translational Research at the Lineberger Cancer Center, The University of North Carolina School of Medicine and Dr. Kwok-Kin Wong, Scientific Director at the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute, Harvard Medical School.
